Trial of AEO in New Glioblastoma (GBM)

Glioblastoma Multiforme Clinical Trial

— AEO  

Official title:

A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04450160
• Other study ID #: Terra-001-201
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: December 2020
• Est. completion date: September 2022

Study information

• Verified date: June 2020
• Source: MetVital, Inc.
• Contact: Alan B Cash, MS
• Phone: 858-947-5722
• Email: acash[@]MetVital.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, Phase 2, Proof-of-concept study in subjects with newly diagnosed glioblastoma multiforme (GBM).

All subjects will receive standard of care therapy for the treatment of their GBM and any Anti-Epileptic Drug (AED) deemed necessary for their surgical resection of the GBM. Patients who are taking concomitant AEDs will be eligible for the study. Treatment with Anhydrous Enol-Oxaloacetate will be added to the Standard of Care.

This study is testing adjuvant Anhydrous Enol-Oxaloacetate (AEO) in GBM, an orally active drug candidate which in animal studies has demonstrated decreased tumor growth rate and increased survival.

Description:

Currently, the multidisciplinary Standard of Care treatment for Glioblastoma multiforme includes maximal surgical resection of the tumor followed by radiotherapy plus concomitant and maintenance temozolomide chemotherapy.This study will treat newly diagnosed GBM patients by adding Anhydrous Enol-Oxaloacetate treatment to their current Standard of Care.

In the body, Anhydrous Enol-Oxaloacetate (AEO) converts into "Oxaloacetate", a metabolite important for many biochemical reactions in the body. On a cellular level, oxaloacetate treatment has been found to modify cancer metabolism in GBM cells, reversing the "Warburg Effect", reducing glycolysis and reducing lactate production. In animals, oxaloacetate treatment has increased survival and reduced tumor growth of implanted GBM tumors.

In other animal studies, oxaloacetate has also shown to have neuo-protective effects including positive effects on seizure development.

.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: September 2022
• Est. primary completion date: July 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • Histopathologic diagnosis of glioblastoma multiforme

• Standard of care maximal feasible surgical resection of the glioma

• Post-operative pre-enrollment MRI-Note: measurable disease is not required

• Concomitant anti-epileptic drugs

• Hemoglobin >9 g/dL

• Platelets >100,000/microliter (mcL)

• <3.0 Upper Limit of Normal Range (ULN) for Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and/or Alkaline Phosphatase

• <2.0 Upper Limit of Normal Range (ULN) for serum creatinine

• Karnofsky performance status >70

• Mentally competent to follow study procedures

• Male and female patients of childbearing potential must agree to use a dual method of contraception (a highly effective method of contraception in conjunction with barrier contraception) consistently and correctly from the first dose of study drug until 90 days after the last dose of study drug

• Able to answer questions on the Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaire

• Subject is willing and able to give informed consent and to follow instructions as per the protocol

Exclusion Criteria:

• • Concomitant treatment with carmustine wafers or tumor-treating electric fields (TTFields)

• QT Interval corrected with the fridericia formula (QTcF) >480ms

• Significant concurrent illness / disease

• Predicted life expectancy < 6 months from date of randomization

• Pregnancy

• Enrollment in another clinical trial during the course of the study

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme

Intervention

Drug:
• Anhydrous Enol-Oxaloacetate (AEO)
Oral supplementation with AEO along with the Standard of Care (Temozolomide)

Other:
• Standard of Care
Standard of Care Temozolomide

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
MetVital, Inc.

References & Publications (3)

Augur ZM, Doyle CM, Li M, Mukherjee P, Seyfried TN. Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma. Front Nutr. 2018 Oct 5;5:91. doi: 10.3389/fnut.2018.00091. eCollection 2018. — View Citation

Ruban A, Berkutzki T, Cooper I, Mohar B, Teichberg VI. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Invest New Drugs. 2012 Dec;30(6):2226-35. doi: 10.1007/s10637-012-9799-5. — View Citation

Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol Lett. 2003 Jul 20;143(2):115-22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival	Measurement of Overall Survival	6 months
Primary	Progression Free Survival-6	Survival at 6 months	6 months
Secondary	Seizures	Time from randomization to first seizure	6 months
Secondary	Chalfont-National Hospital Seizure Severity	Measure of Seizure Severity Ranging from a minimum of 1 to a maximum of 27 with higher score indicating worse outcome	6 months
Secondary	PROMIS-Cancer - Fatigue	Measure of Fatigue Ranging from a minimum of 0 to a maximum of 95 with the higher score indicating worse outcome.	6 months

External Links

•   New Bioanalytical method and single-dose pharmacokinetics for oxaloacetate
•   Oxaloacetate alters glucose metabolism in Glioblastoma
•   Oxaloacetate increases survival in GBM implanted mice